WHO ICTRP trial
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to…
NL-OMON48482 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON48482 |
|---|---|
| Public title | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects with Immune-Mediated Necrotizing Myopathy |
| Scientific title | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects with Immune-Mediated Necrotizing Myopathy - RA101495-02.202 |
| Primary sponsor | PRA Belgium BVBA |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | France;Netherlands;United Kingdom;United States of America |
| Conditions | muscle disorder polymyositis;10028302;muscle disorder;polymyositis |
| Interventions | NA ;Necrotizing Myopathy;Phase 2;Place-controlled |
| Registration date | Mar 12, 2020 |
| Target size | 3 |
| Secondary IDs | 2019 001497 29;NCT04025632;NL72130.018.19 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: